A UK survey of 575 rheumatoid arthritis sufferers highlights the importance of maintaining independence and the significant impact that early diagnosis and treatment can have.
More: continued here
A UK survey of 575 rheumatoid arthritis sufferers highlights the importance of maintaining independence and the significant impact that early diagnosis and treatment can have. Over 94% of those surveyed claimed that their independence was compromised in some way, with over 60% saying it was compromised significantly.
More: continued here
Lyme disease in the U.S. is caused by the tick-borne bacteria Borrelia burgdorferi and usually begins with a skin lesion, after which the bacteria spread throughout the body to the nervous system, heart or joints. About 60 percent of untreated individuals develop arthritis, which affects the knees in particular.
More: continued here
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and the University of Melbourne announced today an agreement to cooperate on investigating new therapeutic applications for MorphoSys’s MOR103 program. MOR103, a HuCAL antibody against human GM-CSF (Granulocyte macrophage-colony stimulating factor), is currently in development for the treatment of rheumatoid arthritis (RA).
More: continued here
POZEN Inc. (NASDAQ:POZN), announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the marketing approval of VIMOVO? (PN 400), the combination of enteric coated (EC) naproxen and immediate release esomeprazole. POZEN and AstraZeneca entered into a global co-development agreement for VIMOVO in August 2006.
More: continued here
For those who are readers of my column you know pretty much what my position is on Osteoarthritis. A top-quality liquid Glucosamine product; exercise; and, a sensible diet.
More: continued here
Aclastaź (zoledronic acid 5 mg)[1] has been approved in the European Union to treat men and post-menopausal women with osteoporosis caused by the long-term use of glucocorticoids, commonly known as steroids.
More: continued here
Treatment with anti-tumor necrosis factor (TNF) agents is recognized as a risk factor for tuberculosis (TB) in patients with immune-mediated inflammatory diseases such as rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, psoriatic arthritis and psoriasis. Most TB cases develop as a result of reactivation of a latent TB infection, and health authorities worldwide recommend screening for latent TB and treating patients before initiating anti-TNF treatment.
More: continued here
What’s the difference between rheumatoid and osteoarthritis? When you think of arthritis, you probably picture joints that start aching as you get older and worsen thanks to excess weight or lack of physical activity .
More: continued here
Though Abbott Laboratories lost a nearly $1.7 billion patent verdict for a blockbuster drug, analysts expect Abbott to negotiate an agreement with court victor Johnson & Johnson that would allow both companies to derive benefits from each other’s drugs.
More: continued here
- July 2009 (15)
- June 2009 (148)
- May 2009 (54)
- April 2009 (51)
- March 2009 (45)
- February 2009 (104)
- November 2008 (38)
- October 2008 (102)
- September 2008 (69)
- August 2008 (110)
- July 2008 (74)
- June 2008 (100)
- May 2008 (62)
- April 2008 (77)
- March 2008 (48)
- February 2008 (63)
- January 2008 (70)
- December 2007 (45)
- November 2007 (83)
- October 2007 (64)
- September 2007 (59)
- August 2007 (75)
- July 2007 (33)
- June 2007 (86)
- May 2007 (54)
- April 2007 (60)
- March 2007 (67)
- February 2007 (77)
- January 2007 (76)
- December 2006 (71)
- November 2006 (154)
- October 2006 (131)
